Search hospitals > Wisconsin > Sheboygan
Vince Lombardi Cancer Clinic-Sheboygan
Claim this profileSheboygan, Wisconsin 53081
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Recurrence
228 reported clinical trials
21 medical researchers
Summary
Vince Lombardi Cancer Clinic-Sheboygan is a medical facility located in Sheboygan, Wisconsin. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Recurrence and other specialties. Vince Lombardi Cancer Clinic-Sheboygan is involved with conducting 228 clinical trials across 337 conditions. There are 21 research doctors associated with this hospital, such as Rubina Qamar, Thomas J. Saphner, Antony Ruggeri, and Michael A Thompson.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
PR positive
Top PIs
Rubina QamarAurora Saint Luke's Medical Center1 year of reported clinical research
Expert in Breast Cancer
Expert in Cancer
26 reported clinical trials
72 drugs studied
Thomas J. SaphnerAurora Saint Luke's Medical Center4 years of reported clinical research
Expert in Cancer
Studies Breast Cancer
27 reported clinical trials
57 drugs studied
Antony RuggeriAurora Cancer Care-Milwaukee West4 years of reported clinical research
Studies Cancer
Studies Solid Tumors
14 reported clinical trials
57 drugs studied
Michael A ThompsonAurora Cancer Care-Milwaukee West3 years of reported clinical research
Studies Multiple Myeloma
Studies Plasma Cell Neoplasms
12 reported clinical trials
29 drugs studied
Clinical Trials running at Vince Lombardi Cancer Clinic-Sheboygan
Breast Cancer
Non-Small Cell Lung Cancer
Cancer
Lung Cancer
Prostate Cancer
Bladder Carcinoma
Renal Cell Carcinoma
Ovarian Cancer
Rectal Cancer
Bladder Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Hormone Therapy with or without Radiation
for Breast Cancer
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Vince Lombardi Cancer Clinic-Sheboygan?
Vince Lombardi Cancer Clinic-Sheboygan is a medical facility located in Sheboygan, Wisconsin. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Recurrence and other specialties. Vince Lombardi Cancer Clinic-Sheboygan is involved with conducting 228 clinical trials across 337 conditions. There are 21 research doctors associated with this hospital, such as Rubina Qamar, Thomas J. Saphner, Antony Ruggeri, and Michael A Thompson.